Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Reaches New 52-Week High – Should You Buy?

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $11.23 and last traded at $11.02, with a volume of 34213 shares traded. The stock had previously closed at $11.15.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, February 3rd.

Fresenius SE & Co. KGaA Price Performance

The stock has a 50 day simple moving average of $9.95 and a two-hundred day simple moving average of $9.38. The company has a market cap of $24.11 billion, a price-to-earnings ratio of 51.38 and a beta of 1.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.36 and a quick ratio of 1.05.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.18 earnings per share for the quarter. The company had revenue of $6.01 billion for the quarter. On average, equities research analysts predict that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current fiscal year.

About Fresenius SE & Co. KGaA

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.